IMPORTANT INFORMATION

  • CFTR.info is an online educational resource on the genetics of cystic fibrosis (CF) and the role of CF transmembrane conductance regulator (CFTR) in normal human physiology as well as in CF.
  • The information contained herein is intended for healthcare professionals working within the European Union (EU).
  • The content of this website has been developed independently by a group of CF healthcare professionals and is for general information purposes only.
  • All of the information about CFTR and CFTR modulators has been obtained from referenced sources and is in the public domain.
  • This website is not intended to promote or advocate a particular course of treatment or any specific drug, whether licensed or unlicensed, nor is it intended to imply or suggest that any drug be used for any purpose other than that which for which it is licensed in the EU.

ABBREVIATED TERMS & CONDITIONS

  • While we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information and related graphics, or products and treatments, contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
  • In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from, or in connection with, the use of this website.
  • Through this website you are able to link to other websites which are not under our control. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
  • Every effort is made to keep the website up and running smoothly. However, we take no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

Please see the full Terms & Conditions before using this website.

 

I have read and understood the above

Drug & research development » Clinical trials » NCT01140451

Extension Study of Ataluren (PTC124) in Cystic Fibrosis

Official title: A Phase 3 Extension Study of Ataluren (PTC124) in Subjects With Nonsense-Mutation-Mediated Cystic Fibrosis

Clinical Trials gov number: NCT01140451

Click on the tabs to move through the sequence.

Purpose: A Phase 3 extension trial to evaluate the long-term safety of ataluren (PTC124) in adult and paediatric patients with nonsense mutation CF, as determined by adverse events and laboratory abnormalities. The study will also assess changes in pulmonary function, CF pulmonary exacerbations, health-related quality of life, antibiotic use for CF-related infections, CF-related disruptions to daily living, body weight, and CF pathophysiology.

Phase: 3

Type: Interventional, open-label, single group assignment

Study sponsor: PTC Therapeutics; Cystic Fibrosis Foundation Therapeutics

  • Completed blinded study drug treatment in the previous Phase 3 study (PTC124-GD-009-CF)
  • Ability to provide written informed consent (parental/guardian consent if applicable)/assent (if <18 years of age)
  • In subjects who are sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during ataluren administration and the 4-week follow up period
  • Willingness and ability to comply with scheduled visits, drug administration plan, study procedures, laboratory tests, and study restrictions

Intervention
Ataluren

Geographical Location
Belgium, Canada, France, Israel, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, United States

Number of Participants
101-1000 (≥6 years)

Primary Endpoint

Adverse events and laboratory abnormalities over 1 year

Secondary Endpoint

Over 1 year

  • Forced expiratory volume in 1 second (FEV1)
  • Forced vital capacity (FVC)
  • Incidence, rate, severity, and duration of pulmonary exacerbations
  • Respiratory HRQL as assessed by the CFQ-R respiratory domain
  • Compliance with study drug treatment

– Ataluren plasma exposure

  • Antibiotic use and hospitalization due to CF-related symptoms
  • Disruptions to school or work due to CF-related symptoms
  • Body weight
  • Lung computerized tomography CF score
  • Nasal transepithelial potential difference
  • Sweat chloride concentration

Click on the tabs to move through the sequence.

  • Experimental: Ataluren (PTC124)

Oral powder for suspension taken 3 times per day (10 mg/kg with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner) for up to 48 weeks.

View Trial Results